Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), New Delhi, India,
Hepatol Int. 2011 Jun;5(2):607-24. doi: 10.1007/s12072-010-9236-9. Epub 2011 Feb 19.
Acute variceal bleeding (AVB) is a medical emergency and associated with a mortality of 20% at 6 weeks. Significant advances have occurred in the recent past and hence there is a need to update the existing consensus guidelines. There is also a need to include the literature from the Eastern and Asian countries where majority of patients with portal hypertension (PHT) live.
The expert working party, predominantly from the Asia-Pacific region, reviewed the existing literature and deliberated to develop consensus guidelines. The working party adopted the Oxford system for developing an evidence-based approach. Only those statements that were unanimously approved by the experts were accepted.
AVB is defined as a bleed in a known or suspected case of PHT, with the presence of hematemesis within 24 h of presentation, and/or ongoing melena, with last melanic stool within last 24 h. The time frame for the AVB episode is 48 h. AVB is further classified as active or inactive at the time of endoscopy. Combination therapy with vasoactive drugs (<30 min of hospitalization) and endoscopic variceal ligation (door to scope time <6 h) is accepted as first-line therapy. Rebleeding (48 h of T (0)) is further sub-classified as very early rebleeding (48 to 120 h from T (0)), early rebleeding (6 to 42 days from T (0)) and late rebleeding (after 42 days from T (0)) to maintain uniformity in clinical trials. Emphasis should be to evaluate the role of adjusted blood requirement index (ABRI), assessment of associated comorbid conditions and poor predictors of non-response to combination therapy, and proposed APASL (Asian Pacific Association for Study of the Liver) Severity Score in assessing these patients. Role of hepatic venous pressure gradient in AVB is considered useful. Antibiotic (cephalosporins) prophylaxis is recommended and search for acute ischemic hepatic injury should be done. New guidelines have been developed for management of variceal bleed in patients with non-cirrhotic PHT and variceal bleed in pediatric patients.
Management of acute variceal bleeding in Asia-Pacific region needs special attention for uniformity of treatment and future clinical trials.
急性静脉曲张出血 (AVB) 是一种医疗急症,6 周时的死亡率为 20%。在最近的过去取得了重大进展,因此有必要更新现有的共识指南。还需要包括来自东亚和亚洲国家的文献,因为大多数门脉高压 (PHT) 患者都生活在这些国家。
主要来自亚太地区的专家工作组审查了现有文献并进行了审议,以制定共识指南。工作组采用了牛津系统来制定循证方法。只有那些得到专家一致认可的陈述才被接受。
AVB 定义为在已知或疑似 PHT 的病例中出现出血,在出现症状的 24 小时内出现呕血,和/或持续黑便,最后一次黑便发生在过去 24 小时内。AVB 发作的时间框架为 48 小时。在进行内镜检查时,AVB 进一步分为活动期或非活动期。血管活性药物联合治疗(<30 分钟的住院时间)和内镜下静脉曲张结扎术(从门到镜时间 <6 小时)被接受为一线治疗。再出血(T (0) 后的 48 小时)进一步细分为非常早期再出血(从 T (0) 开始的 48 至 120 小时)、早期再出血(T (0) 后的 6 至 42 天)和晚期再出血(T (0) 后的 42 天后),以保持临床试验的一致性。应强调评估调整后的血需求指数 (ABRI) 的作用、评估相关合并症和对联合治疗无反应的不良预测因素,以及提出的 APASL(亚太肝脏研究协会)严重程度评分来评估这些患者。肝静脉压力梯度在 AVB 中的作用被认为是有用的。建议预防性使用抗生素(头孢菌素),并应寻找急性缺血性肝损伤。已经为非肝硬化性 PHT 患者和儿科患者的静脉曲张出血制定了新的管理指南。
亚太地区急性静脉曲张出血的管理需要特别注意治疗的一致性和未来的临床试验。